Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery

被引:23
作者
Ruiz Castro, Beatriz Guerreiro [1 ]
dos Reis, Ricardo [2 ]
Cintra, Georgia Fontes [2 ]
de Assuncao Sousa, Mileide Maria [2 ]
Vieira, Marcelo de Andrade [2 ]
Mattos da Cunha Andrade, Carlos Eduardo [1 ,2 ]
机构
[1] Dr Paulo Prata FACISB, Barretos Sch Hlth Sci, Sao Paulo, Brazil
[2] Barretos Canc Hosp, Gynecol Oncol Dept, Barretos, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Ovarian cancer; Surgical morbidity; Chemotherapy delay; Complication; Debulking; ADVANCED EPITHELIAL OVARIAN; PRIMARY CYTOREDUCTIVE SURGERY; GYNECOLOGIC-ONCOLOGY-GROUP; NEOADJUVANT CHEMOTHERAPY; STAGE-III; FALLOPIAN-TUBE; SURVIVAL; RISK; OUTCOMES; COMPLICATIONS;
D O I
10.1097/IGC.0000000000001325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Postoperative complications and adjuvant chemotherapy delay (ACD) are the most damaging outcomes after surgical treatment of advanced ovarian cancer. Establishing predictive factors should prevent their occurrence. Methods: We analyzed retrospectively all patients with advanced ovarian cancer who underwent cytoreduction at our institution between December 2010 and May 2016. We evaluated all 30-day complications and considered ACD all cases who did not start adjuvant chemotherapy until 42 days or did not perform it after cytoreductive surgery. These data were analyzed in the general group, and between primary debulking surgery (PDS) and interval debulking surgery (IDS) using chi(2) test and Student t test. Relationship of variables was verified using Multiple Logistic Regression. Results: A total of 83 women were included. Of these, 43 (51.8%) were submitted to PDS and 40 (48.2%) to IDS. In the PDS group, 23 (53.5%) of the patients had complications. For the IDS group, 27 (67.5%) complicated (P = 0.192). Regarding the general group, independent predictors for 30-day complications were presence of comorbidities (odds ratio [OR], 5.466, 95% confidence interval [CI], 1.151-25,972; P = 0.033) and estimated blood loss of greater than 300 mL (OR, 14.407; 95% CI, 2.736-75.863; P = 0.002). In multivariate analysis of the general group, independent predictors for ACD were the presence of hypertension as comorbidity (OR, 3.898; 95% CI, 1.119-13.578; P = 0.033), body mass index of greater than 30 kg/m(2) (OR, 5.728; 95% CI, 1.169-28.069; P = 0.031), 30-day reoperation (OR, 21.275; 95% CI, 1.799-251.651; P = 0.015), and fever within 30 days (OR, 11.594; 95% CI, 1.714-78.412; P = 0.012). Conclusions: Comorbidities and intraoperative bleeding are the most relevant findings related to surgical complications. Surgical approach (PDS or IDS) was not related with complications. Surgical complications were significantly related to ACD.
引用
收藏
页码:1520 / 1528
页数:9
相关论文
共 32 条
  • [1] Aggressive surgical effort and improved survival in advanced-stage ovarian cancer
    Aletti, GD
    Dowdy, SC
    Gostout, BS
    Jones, MB
    Stanhope, CR
    Wilson, TO
    Podratz, KC
    Cliby, WA
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) : 77 - 85
  • [2] A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model
    Aletti, Giovanni D.
    Santillan, Antonio
    Eisenhauer, Eric L.
    Hu, Jae
    Aletti, Giacomo
    Podratz, Karl C.
    Bristow, Robert E.
    Chi, Dennis S.
    Cliby, William A.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 107 (01) : 99 - 106
  • [3] Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment
    Aletti, Giovanni D.
    Eisenhauer, Eric L.
    Santillan, Antonio
    Axtell, Allison
    Aletti, Giacomo
    Holschneider, Christine
    Chi, Dennis S.
    Bristow, Robert E.
    Cliby, William A.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 23 - 28
  • [4] Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery
    Ataseven, Beyhan
    du Bois, Andreas
    Reinthaller, Alexander
    Traut, Alexander
    Heitz, Florian
    Aust, Stefanie
    Prader, Sonia
    Polterauer, Stephan
    Harter, Philipp
    Grimm, Christoph
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 560 - 565
  • [5] A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery
    Barber, Emma L.
    Rutstein, Sarah
    Miller, William C.
    Gehrig, Paola A.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 401 - 406
  • [6] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    Bristow, RE
    Tomacruz, RS
    Armstrong, DK
    Trimble, EL
    Montz, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1248 - 1259
  • [7] What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi, D. S.
    Eisenhauer, E. L.
    Lang, J.
    Huh, J.
    Haddad, L.
    Abu-Rustum, N. R.
    Sonoda, Y.
    Levine, D. A.
    Hensley, M.
    Barakat, R. R.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 559 - 564
  • [8] The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas
    Chi, Dennis S.
    Zivanovic, Oliver
    Levinson, Kimberly L.
    Kolev, Valentin
    Huh, Jae
    Dottino, Joseph
    Gardner, Ginger J.
    Leitao, Mario M., Jr.
    Levine, Douglas A.
    Sonoda, Yukio
    Abu-Rustum, Nadeem R.
    Brown, Carol L.
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 119 (01) : 38 - 42
  • [9] Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
    Fagotti, Anna
    Ferrandina, Gabriella
    Vizzielli, Giuseppe
    Fanfani, Francesco
    Gallotta, Valerio
    Chiantera, Vito
    Costantini, Barbara
    Margariti, Pasquale Alessandro
    Alletti, Salvatore Gueli
    Cosentino, Francesco
    Tortorella, Lucia
    Scambia, Giovanni
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 59 : 22 - 33
  • [10] Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer
    Gerestein, C. G.
    Nieuwenhuyzen-de Boer, G. M.
    Eijkemans, M. J.
    Kooi, G. S.
    Burger, C. W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 102 - 109